LSV Asset Management
AMRX icon

LSV Asset Management’s Amneal Pharmaceuticals AMRX Stock Holding History

LSV Asset Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.42M Hold
197,300
– – 0.01% 548
2026
Q1 		$2.45M Hold
197,300
– – 0.01% 550
2025
Q4 		$2.49M Hold
197,300
– – 0.01% 562
2025
Q3 		$1.98M Buy
197,300
+27,400
+16% +$246K ﹤0.01% 576
2025
Q2 		$1.37M Hold
169,900
– – ﹤0.01% 588
2025
Q1 		$1.42M Buy
+169,900
New +$1.42M ﹤0.01% 595
2024
Q3 		– Sell
-1,057,300
Closed -$6.71M – 824
2024
Q2 		$6.71M Sell
1,057,300
-8,300
-0.8% -$52.7K 0.01% 482
2024
Q1 		$6.46M Sell
1,065,600
-23,700
-2% -$134K 0.01% 495
2023
Q4 		$6.61M Sell
1,089,300
-340,000
-24% -$1.51M 0.01% 492
2023
Q3 		$6.03M Buy
1,429,300
+136,100
+11% +$508K 0.01% 497
2023
Q2 		$4.01M Sell
1,293,200
-104,000
-7% -$222K 0.01% 543
2023
Q1 		$1.94M Hold
1,397,200
– – ﹤0.01% 609
2022
Q4 		$2.78M Hold
1,397,200
– – 0.01% 563
2022
Q3 		$2.82M Sell
1,397,200
-135,000
-9% -$378K 0.01% 561
2022
Q2 		$4.87M Sell
1,532,200
-20,000
-1% -$72.5K 0.01% 513
2022
Q1 		$6.47M Sell
1,552,200
-19,000
-1% -$84.1K 0.01% 494
2021
Q4 		$7.53M Buy
1,571,200
+25,600
+2% +$128K 0.01% 490
2021
Q3 		$8.25M Hold
1,545,600
– – 0.01% 476
2021
Q2 		$7.91M Buy
1,545,600
+282,000
+22% +$1.6M 0.01% 491
2021
Q1 		$8.5M Buy
1,263,600
+171,800
+16% +$952K 0.01% 491
2020
Q4 		$4.99M Sell
1,091,800
-21,500
-2% -$95.3K 0.01% 557
2020
Q3 		$4.32M Buy
1,113,300
+177,500
+19% +$759K 0.01% 555
2020
Q2 		$4.45M Buy
935,800
+580,000
+163% +$2.39M 0.01% 558
2020
Q1 		$1.24M Sell
355,800
-11,800
-3% -$50K ﹤0.01% 700
2019
Q4 		$1.77M Hold
367,600
– – ﹤0.01% 690
2019
Q3 		$1.07M Buy
+367,600
New +$1.28M ﹤0.01% 739

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
WW
Westshore Wealth Newport Beach, California $322M AUM 24.46% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

LSV Asset Management's AMRX Position: Q2 2026 in Review

LSV Asset Management held its Amneal Pharmaceuticals (AMRX) position steady in Q2 2026 at 197,300 shares worth $3.42M. The position accounts for 0.01% of the portfolio, ranked #548.

LSV Asset Management first reported a position in AMRX in Q3 2019 and has held it in 26 quarters since. The position peaked at $8.5M in Q1 2021. 136 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • LSV Asset Management held 197,300 shares of Amneal Pharmaceuticals worth $3.42M as of Q2 2026.
  • LSV Asset Management left its Amneal Pharmaceuticals share count unchanged in Q2 2026.
  • Amneal Pharmaceuticals made up 0.01% of LSV Asset Management's portfolio in Q2 2026, its #548 holding.
  • LSV Asset Management first reported a position in Amneal Pharmaceuticals in Q3 2019 and has held it in 26 quarters since.
  • LSV Asset Management's Amneal Pharmaceuticals position peaked at $8.5M in Q1 2021.
  • 136 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on LSV Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.